4024259 L JUN 2 0 2003
New Star Lasers, Inc.
UV-300 Pulsed Light Therapy System
510(k) Premarket Notification
510(k) SUMMARY
: Submitter: New Star Lasers, Inc.
Address: 9085 Foothills Boulevard
Roseville, CA 95747
Contact Person: Donald V. Johnson
Vice-President of Operations
Telephone: (916) 677-1912
Facsimile: (916) 677-1901
Date Prepared: December 20, 2002
Device Trade Name: UV-300 Pulsed Light Therapy System
Common Name: Pulsed Light for Thermolysis/Photoepilation
Classification Name: Instrument, Surgical, Powered, Laser.
79-GEX, 21 C.F.R. § 878.4810
Legally Marketed Predicate Lumenis, Inc. JPL Quantum, K020839
Devices: Lumenis, Inc. Bclear, K020591
Radiancy, Inc. SpaTouch, K020856
Palomar, Inc. EsteLux, K020453
Alderm/MBC Prolite/Plasmalite, K013365, K022568
Description of the New Star UV-300 The New Star UV-300 Pulsed Light Therapy System is a
Pulsed Light Therapy System: compact, self-contained system that delivers a beam of
pulsed light at wavelengths of 300nm to 1400nm, which
can be optimized at various wavelength ranges and
delivered to the treatment site. The system consists of a
control console unit, which houses the power supply,
cooling system, cryogen source, and microcontroller, the
handpiece, which contains the light source, and the
footswitch.
Intended use of the New Star UV- The New Star Lasers UV-300 Pulsed Light Therapy
300 Pulsed Light Therapy System: System is indicated for the treatment of psoriasis,
vitiligo, atopic dermatitis (eczema), seborrheic
dermatitis, vascular lesions, rosacea, hemangiomas, leg
veins, hair removal, and tattoos.
ae

A Yy
- Aw L
KEY 257

Nonclinical Performance Data: None.

Clinical Performance Data: None.

Conclusion: The New Star Lasers UV-300 Pulsed Light Therapy
System is substantially equivalent to other existing
pulsed light systems in commercial distribution for
treatment of psoriasis, vitiligo, atopic dermatitis
(eczema) seborrheic dermatitis, vascular lesions,
rosacea, hemangiomas, leg veins, hair removal, and
tattoos.

Additional Information: None requested at this time

aa,
f DEPARTMENT OF HEALTH & HUMAN SERVICES Public Health Service
LG
mm Food and Drug Administration
9200 Corporate Boulevard
Rockville MD 20850
JUN 2 0 2003
Mr. Donald V. Johnson
Vice President of Operations
New Star Lasers, Inc.
9085 Foothills Boulevard
Roseville, California 95747
Re: K024259
Trade/Device Name: UV-300 Pulsed Light Therapy System
Regulation Number: 21 CFR 878.4810
Regulation Name: Laser surgical instrument for use in general
and plastic surgery and in dermatology
Regulatory Class: II
Product Code: GEX
Dated: March 21, 2003
Received: March 24, 2003
Dear Mr. Johnson:
We have reviewed your Section 510(k) premarket notification of intent to market the device
referenced above and have determined the device is substantially equivalent (for the indications
for use stated in the enclosure) to legally marketed predicate devices marketed in interstate
commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to
devices that have been reclassified in accordance with the provisions of the Federal Food, Drug,
and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA).
: You may, therefore, market the device, subject to the general controls provisions of the Act. The
general controls provisions of the Act include requirements for annual registration, listing of
devices, good manufacturing practice, labeling, and prohibitions against misbranding and ~
adulteration.
If your device is classified (see above) into either class [I (Special Controls) or class III (PMA), it
may be subject to such additional controls. Existing major regulations affecting your device can
be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may
publish further announcements concerning your device in the Federal Register.
Please be advised that FDA’s issuance of a substantial equivalence determination does not mean
that FDA has made a determination that your device complies with other requirements of the Act
or any Federal statutes and regulations administered by other Federal agencies. You must
comply with all the Act’s requirements, including, but not limited to: registration and listing (21
CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic
product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Page 2 - Mr. Donald V. Johnson
This letter will allow you to begin marketing your device as described in your Section 510(k)
premarket notification. The FDA finding of substantial equivalence of your device to a legally
marketed predicate device results in a classification for your device and thus, permits your device
to proceed to the market.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please
contact the Office of Compliance at (301) 594-4659. Additionally, for questions on the
promotion and advertising of your device, please contact the Office of Compliance at (301) 5944639. Also, please note the regulation entitled, "Misbranding by reference to premarket
notification” (21CFR Part 807.97) you may obtain. Other general information on your
responsibilities under the Act may be obtained from the Division of Small Manufacturers,
International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597
or at its Internet address http://www.fda.gow/cdrh/dsma/dsmamain.html

Sincerely yours, ,

Miran Covet

ceiia M. Witten, Ph.D., M.D.
Director
Division of General, Restorative
and Neurological Devices
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

INDICATION FOR USE STATEMENT
. As
$10(k) Number: KOA F235 7
Device Name: New Star Lasers UV-300 Pulsed Light Therapy System
Indications for Use:
The New Star Lasers UV-300 Pulsed Light Therapy System is indicated for the
treatment of facial, truncal or leg telangiectasia and/or reticular veins, rosasia,
port wine stains, hemangiomas, psoriasis, vitiligo, vascular lesions, atopic
dermatitis (eczema), seborrheic dermatitis, hair removal, and tattoos. The UV300 may be used to treat patients with skin types I-VI.
(Please do not write below this line - Continue on another page if needed)
Concurrence of CDRH, Office of Device Evaluation (ODE)
Prescription Use OR Over-the-Counter Use
(per 21 CFR 801.199)
Theva 0-Praprnr
(ivision Sign-Off)
Division of General, Restorative
and Neurological Devices
510(k) Number 8927257

